Posted by Michael Wonder on 06 Dec 2024
Does NICE’s “severity modifier” for assessing diseases need to change?
22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in England and Wales after negotiations collapsed over pricing.
Jacqui Wise examines calls for NICE to rethink its weighting system for evaluating new treatments.
Trastuzumab deruxtecan (Enhertu), made by Daiichi Sankyo and AstraZeneca, is a treatment for adult patients with unresectable or metastatic HER2 low breast cancer who have received previous chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. In December 2023 the drug was approved for use on the NHS in Scotland after the Scottish Medicines Consortium used its own method to reach its decision.
